Clinical data
Trade names Sundralen, Symcorad, Symcor
ATC code C02AC (WHO)
Pharmacokinetic data
Biological half-life 2.3–5 hours[1]
CAS Number 31428-61-2 N
PubChem (CID) 39974
ChemSpider 36548 YesY
UNII 195V08O55G YesY
KEGG D06127 YesY
Chemical and physical data
Formula C8H10ClN3S
Molar mass 215.70 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Tiamenidine (BAN, USAN, INN, also known as thiamenidine, Hoe 440) is a imidazoline compound that shares many of the pharmacological properties of clonidine. It acts as a centrally-acting α1 and α2 adrenergic receptor antagonist (with IC50 4.85 μM and 0.0091 μM, respectively).[2] In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output.[3] It was marketed (as tiamenidine hydrochloride) by Sanofi-Aventis[4] under the brand name Sundralen[5] for the management of essential hypertension.[6]


Tiamenidine synthesis:[7]

Reaction of thiourea 1 with methyl iodide gives the corresponding S-methyl analogue (2), followed by heating with ethylenediamine, completes the synthesis of tiamenidine (3).

See also


  1. Eckert, HG; Baudner, S; Weimer, KE; Wissmann, H (1981). "Determination of Tiamenidine in Biological Specimens by Radioimmunoassay". Arzneimittel-Forschung. 31 (3): 419–24. PMID 7194666.
  2. Timmermans, PB; de Jonge, A; Thoolen, MJ; Wilffert, B; Batink, H; van Zwieten, PA (April 1984). "Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.". Journal of Medicinal Chemistry. 27 (4): 495–503. doi:10.1021/jm00370a011. PMID 6142954.
  3. Roden, DM; Nadeau, JH; Primm, RK (June 1988). "Electrophysiologic and Hemodynamic Effects of Chronic Oral Therapy With the Alpha 2-agonists Clonidine and Tiamenidine in Hypertensive Volunteers". Clinical Pharmacology and Therapeutics. 43 (6): 648–54. doi:10.1038/clpt.1988.90. PMID 2897889.
  4. "Pharmaceutical and healthcare online databases. Tiamenidine Hydrochloride". Drugs-About.com. Retrieved 30 November 2015.
  5. Ganten, D; Mulrow, Patrick J., eds. (2013). Pharmacology of Antihypertensive Therapeutics (1st ed.). [S.l.]: Springer-Verlag Berlin Heidelberg. p. 880. ISBN 978-3-642-74211-8.
  6. Zamboulis, C; Hossmann, V; Dollery, CT; Eckert, H (October 1979). "Tiamenidine, a Centrally Acting Antihypertensive Drug in Essential Hypertension [proceedings].". British Journal of Clinical Pharmacology. 8 (4): 390. PMID 508528.
  7. Rippel, H.; Ruschig, H.; Linder, E.; Schorr, M.; 1973, U.S. Patent 3,758,476
This article is issued from Wikipedia - version of the 9/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.